08:58:41 EDT Sat 18 May 2024
Enter Symbol
or Name
USA
CA



Arch Biopartners Inc
Symbol ARCH
Shares Issued 62,398,815
Close 2023-07-31 C$ 2.07
Market Cap C$ 129,165,547
Recent Sedar Documents

Arch Biopartners hires ITG as market-maker

2023-07-31 18:20 ET - News Release

Mr. Richard Muruve reports

ARCH BIOPARTNERS ENGAGES INDEPENDENT TRADING GROUP AS MARKET MAKER

Arch Biopartners Inc. has engaged the services of Independent Trading Group (ITG) to provide market-making services in accordance with TSX Venture Exchange policies, subject to regulatory approval. ITG will trade shares of the company on the TSX-V and all other trading venues with the objective of maintaining a reasonable market and improving the liquidity of the company's common shares.

Under the agreement, ITG will receive compensation of $5,000 per month. The agreement is effective June 1, 2023, for an initial term of three months and will renew for additional one-month terms unless terminated. The agreement may be terminated by either party with 30 days of notice. There are no performance factors contained in the agreement and ITG will not receive shares or options as compensation. ITG and the company are unrelated and unaffiliated entities and at the time of the agreement, neither ITG nor its principals have an interest, directly or indirectly, in the securities of the company.

ITG is a Toronto-based Investment Industry Regulatory Organization (IIROC) dealer-member that specializes in market-making, liquidity provision, agency execution, ultralow-latency connectivity and bespoke algorithmic trading solutions. Established in 1992, with a focus on market structure, execution and trading, ITG has leveraged its own proprietary technology to deliver high-quality liquidity provision and execution services to a broad array of public issuers and institutional investors.

About Arch Biopartners Inc.

Arch Biopartners is a late-stage clinical trial company focused on preventing inflammation and acute organ injury. The company is developing new drug candidates that inhibit inflammation in the lungs, kidneys and liver via the dipeptidase-1 (DPEP-1) pathway and are relevant for common injuries and chronic diseases where organ inflammation is an unmet problem.

The company has 62,598,825 common shares outstanding.

We seek Safe Harbor.

© 2024 Canjex Publishing Ltd. All rights reserved.